参考文献/References:
[1] Masiello E,Veronesi G,Gallo D,et al.Antithyroid drug treatment for Graves' disease:baseline predictive models of relapse after treatment for a patient-tailored management[J].J Endocrinol Invest,2018,41(12):1425-1432.DOI:10.1007/s40618-018-0918-9.
[2] 周鹏,赵月婷,陈国芳,等.抗甲状腺药物治疗Graves病复发风险因素及预测模型的研究进展[J].中华内分泌代谢杂志,2019,35(12):1068-1072.DOI:10.3760/cma.j.issn.1000-6699.2019.12.014.
[3] 崔雯锦,赵月婷,徐书杭,等.影响抗甲状腺药物治疗Graves病预后因素的研究[J].中华内分泌代谢杂志,2021,37(9):773-781.DOI:10.3760/cma.j.cn311282-20210316-00167.
[4] Vos XG,Endert E,Zwinderman AH,et al.Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism[J].J Clin Endocrinol Metab,2016,101(4):1381-1389.DOI:10.1210/ jc.2015-3644.
[5] Bartalena L,Masiello E,Magri F,et al.The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past:results of a large observational longitudinal study[J].J Endocrinol Invest,2016,39(12):1445-1451.DOI:10.1007/s40618-016-0516-7.
[6] Salvi M,Covelli D.B cells in Graves' orbitopathy:more than just a source of antibodies[J].Eye(Lond),2019,33(2):230-234.DOI:10.1038/s41433-018-0285-y.
[7] El Fassi D,Nielsen CH,Bonnema SJ,et al.B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease:a controlled pilot study[J].J Clin Endocrinol Metab,2007,92(5):1769-1772.DOI:10.1210/jc.2006-2388.
[8] Cheetham TD,Cole M,Abinun M,et al.Adjuvant rituximab-exploratory trial in young people with Graves'disease[J].J Clin Endocrinol Metab,2022,107(3):743-754.DOI:10.1210/clinem/dgab763.
[9] Kahaly GJ,Stan MN,Frommer L,et al.A novel anti-CD40 monoclonal antibody,iscalimab,for control of Graves hyperthyroidism-a proof-of-concept trial[J].J Clin Endocrinol Metab,2020,105(3):dgz013.DOI:10.1210/clinem/dgz013.
[10] Blumberg LJ,Humphries JE,Jones SD,et al.Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses[J].Sci Adv,2019,5(12):eaax9586.DOI:10.1126/sciadv.aax9586.
[11] Ulrichts P,Guglietta A,Dreier T,et al.Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans[J].J Clin Invest,2018,128(10):4372-4386.DOI:10.1172/JCI97911.
[12] Robak T,Kaz'mierczak M,Jarque I,et al.Phase 2 multiple-dose study of an FcRn inhibitor,rozanolixizumab,in patients with primary immune thrombocytopenia[J].Blood Adv,2020,4(17):4136-4146.DOI:10.1182/bloodadvances.2020002003.
[13] Lin JD,Wang YH,Fang WF,et al.Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease[J].Clin Chim Acta,2016,462:96-102.DOI:10.1016/j.cca.2016.09.004.
[14] Campi I,Tosi D,Rossi S,et al.B cell activating factor(BAFF)and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases[J].Thyroid,2015,25(9):1043-1049. DOI:10.1089/thy.2015.0029.
[15] Lane LC,Cheetham TD,Perros P,et al.New therapeutic horizons for Graves' hyperthyroidism[J].Endocr Rev,2020,41(6):873-884.DOI:10.1210/endrev/bnaa022.
[16] Neumann S,Nir EA,Eliseeva E,et al.A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice[J].Endocrinol,2014,155(1):310-314.DOI:10.1210/en.2013-1835.
[17] Furmaniak J,Sanders J,Young S,et al.In vivo effects of a human thyroid-stimulating monoclonal autoantibody(M22)and a human thyroid-blocking autoantibody(K1-70)[J].Auto Immun Highlights,2011,3(1):19-25.DOI:10.1007/s13317-011-0025-9.
[18] Pearce SHS,Dayan C,Wraith DC,et al.Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism:a phase I study[J].Thyroid,2019,29(7):1003-1011.DOI:10.1089/thy.2019.0036.
[19] Jang JY,Choi SY,Park I,et al.VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis[J].EMBO Mol Med,2017,9(6):750-769.DOI:10.15252/emmm.201607341.
[20] Rancier M,Zaaber I,Stathopoulou MG,et al.Pro-and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases[J].Autoimmunity,2016,49(6):366-372.DOI:10.1080/08916934.2016.1199019.
[21] Okamoto M,Watanabe M,Inoue N,et al.Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto's disease and the intractability of Graves' disease,respectively[J].Endocr J,2020,67(5):545-559.DOI:10.1507/endocrj.EJ19-0480.
[22] 陈建发,杨雪丰,陈引香,等.超声引导下经皮穿刺微波消融术治疗Graves病30例效果观察[J].广东医科大学学报,2017,35(5):528-531.DOI:10.3969/j.issn.1005-4057.2017.05.020.
[23] Lang BH,Woo YC,Wong IY,et al.Single-session high-intensity focused ultrasound treatment for persistent or relapsed Graves disease:preliminary experience in a prospective study[J].Radiol,2017,285(3):1011-1022.DOI:10.1148/radiol.2017162776.
[24] Lang BH,Woo YC,Chiu KW.Two-year outcomes of single-session high-intensity focused ultrasound(HIFU)treatment in persistent or relapsed Graves' disease[J].Eur Radiol,2019,29(12):6690-6698.DOI:10.1007/s00330-019-06303-8.
相似文献/References:
[1]陈晓铭 胡卓清 李潍 刘美莲 吴美芬 方烁 武革.CD40-1C/T多态性（rs1883832）与粤西汉族人Graves病的关系[J].国际内分泌代谢杂志,2015,(01):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
Chen Xiaoming,Hu Zhuoqing,Li Wei,et al.Relationship between CD40-1C/T polymorphism（rs1883832）and Graves′ disease of Han population in western region of Guangdong province[J].International Journal of Endocrinology and Metabolism,2015,(04):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
[2]赵永强,田德增,魏晓华,等.不同治疗方法对Graves病患者外周血淋巴细胞亚群的影响[J].国际内分泌代谢杂志,2015,(04):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
Zhao Yongqiang*,Tian Dezeng,Wei Xiaohua,et al.Effects of different therapeutic methods on peripheral blood lymphocyte subgroups in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2015,(04):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
[3]瞿茹怡,李圣贤,陆咏,等.2q33区基因多态性与Graves病发病风险的研究[J].国际内分泌代谢杂志,2014,(02):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
Qu Ruyi*,Li Shengxian,Lu Yong,et al.Association between 2q33 gene polymorphism and Graves' disease[J].International Journal of Endocrinology and Metabolism,2014,(04):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
[4]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的
相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(04):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
[5]马金刚 魏红丽 尚恒.Graves病患者外周血T细胞亚群与甲状腺
功能及甲状腺自身抗体间的相关性分析[J].国际内分泌代谢杂志,2020,40(01):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
Ma Jingang,Wei Hongli,Shang Heng.Correlation between peripheral blood T cell subsets and thyroid function and thyroid autoantibodies in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2020,40(04):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
[6]陆东宁,徐加杰,葛明华.甲状腺球蛋白在分化型甲状腺癌复发转移诊治中的研究进展[J].国际内分泌代谢杂志,2022,42(06):465.[doi:10.3760/cma.j.cn121383-20210930-09092]
Lu Dongning,Xu Jiajie,Ge Minghua..Research progress of thyroglobulin in the diagnosis and treatment of recurrence and metastasis of differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2022,42(04):465.[doi:10.3760/cma.j.cn121383-20210930-09092]
[7]陈莹 徐书杭.2022年欧洲甲状腺学会《儿童Graves病管理指南》解读[J].国际内分泌代谢杂志,2023,43(05):449.[doi:10.3760/cma.j.cn121383-20220629-06064]
Chen Ying,Xu Shuhang.Interpretation of 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease[J].International Journal of Endocrinology and Metabolism,2023,43(04):449.[doi:10.3760/cma.j.cn121383-20220629-06064]